Unicycive Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 3.74 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 104.18M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj...